Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

Nathan A. Berger, Valerie C. Besson, A. Hamid Boulares, Alexander Bürkle, Alberto Chiarugi, Robert S. Clark, Nicola J. Curtin, Salvatore Cuzzocrea, Ted M. Dawson, Valina L. Dawson, György Haskó, Lucas Liaudet, Flavio Moroni, Pál Pacher, Peter Radermacher, Andrew L. Salzman, Solomon H. Snyder, Francisco Garcia Soriano, Robert P. Strosznajder, Balázs Sümegi & 2 others Raymond A. Swanson, Csaba Szabo

    Research output: Contribution to journalArticle

    39 Citations (Scopus)

    Abstract

    The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.

    Original languageEnglish (US)
    JournalBritish Journal of Pharmacology
    DOIs
    StateAccepted/In press - 2017

    Fingerprint

    Acute Lung Injury
    Therapeutics
    Septic Shock
    DNA Repair
    Pancreatitis
    Multiple Sclerosis
    Parkinson Disease
    Chronic Disease
    Asthma
    Stroke
    Odds Ratio
    Poly(ADP-ribose) Polymerase Inhibitors
    Enzymes
    olaparib
    Traumatic Brain Injury

    ASJC Scopus subject areas

    • Pharmacology

    Cite this

    Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. / Berger, Nathan A.; Besson, Valerie C.; Boulares, A. Hamid; Bürkle, Alexander; Chiarugi, Alberto; Clark, Robert S.; Curtin, Nicola J.; Cuzzocrea, Salvatore; Dawson, Ted M.; Dawson, Valina L.; Haskó, György; Liaudet, Lucas; Moroni, Flavio; Pacher, Pál; Radermacher, Peter; Salzman, Andrew L.; Snyder, Solomon H.; Soriano, Francisco Garcia; Strosznajder, Robert P.; Sümegi, Balázs; Swanson, Raymond A.; Szabo, Csaba.

    In: British Journal of Pharmacology, 2017.

    Research output: Contribution to journalArticle

    Berger, NA, Besson, VC, Boulares, AH, Bürkle, A, Chiarugi, A, Clark, RS, Curtin, NJ, Cuzzocrea, S, Dawson, TM, Dawson, VL, Haskó, G, Liaudet, L, Moroni, F, Pacher, P, Radermacher, P, Salzman, AL, Snyder, SH, Soriano, FG, Strosznajder, RP, Sümegi, B, Swanson, RA & Szabo, C 2017, 'Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases', British Journal of Pharmacology. https://doi.org/10.1111/bph.13748
    Berger, Nathan A. ; Besson, Valerie C. ; Boulares, A. Hamid ; Bürkle, Alexander ; Chiarugi, Alberto ; Clark, Robert S. ; Curtin, Nicola J. ; Cuzzocrea, Salvatore ; Dawson, Ted M. ; Dawson, Valina L. ; Haskó, György ; Liaudet, Lucas ; Moroni, Flavio ; Pacher, Pál ; Radermacher, Peter ; Salzman, Andrew L. ; Snyder, Solomon H. ; Soriano, Francisco Garcia ; Strosznajder, Robert P. ; Sümegi, Balázs ; Swanson, Raymond A. ; Szabo, Csaba. / Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. In: British Journal of Pharmacology. 2017.
    @article{6f0f299fd72b492b93b1006268f28d41,
    title = "Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases",
    abstract = "The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.",
    author = "Berger, {Nathan A.} and Besson, {Valerie C.} and Boulares, {A. Hamid} and Alexander B{\"u}rkle and Alberto Chiarugi and Clark, {Robert S.} and Curtin, {Nicola J.} and Salvatore Cuzzocrea and Dawson, {Ted M.} and Dawson, {Valina L.} and Gy{\"o}rgy Hask{\'o} and Lucas Liaudet and Flavio Moroni and P{\'a}l Pacher and Peter Radermacher and Salzman, {Andrew L.} and Snyder, {Solomon H.} and Soriano, {Francisco Garcia} and Strosznajder, {Robert P.} and Bal{\'a}zs S{\"u}megi and Swanson, {Raymond A.} and Csaba Szabo",
    year = "2017",
    doi = "10.1111/bph.13748",
    language = "English (US)",
    journal = "British Journal of Pharmacology",
    issn = "0007-1188",
    publisher = "Wiley-Blackwell",

    }

    TY - JOUR

    T1 - Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

    AU - Berger, Nathan A.

    AU - Besson, Valerie C.

    AU - Boulares, A. Hamid

    AU - Bürkle, Alexander

    AU - Chiarugi, Alberto

    AU - Clark, Robert S.

    AU - Curtin, Nicola J.

    AU - Cuzzocrea, Salvatore

    AU - Dawson, Ted M.

    AU - Dawson, Valina L.

    AU - Haskó, György

    AU - Liaudet, Lucas

    AU - Moroni, Flavio

    AU - Pacher, Pál

    AU - Radermacher, Peter

    AU - Salzman, Andrew L.

    AU - Snyder, Solomon H.

    AU - Soriano, Francisco Garcia

    AU - Strosznajder, Robert P.

    AU - Sümegi, Balázs

    AU - Swanson, Raymond A.

    AU - Szabo, Csaba

    PY - 2017

    Y1 - 2017

    N2 - The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.

    AB - The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.

    UR - http://www.scopus.com/inward/record.url?scp=85016419081&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85016419081&partnerID=8YFLogxK

    U2 - 10.1111/bph.13748

    DO - 10.1111/bph.13748

    M3 - Article

    JO - British Journal of Pharmacology

    JF - British Journal of Pharmacology

    SN - 0007-1188

    ER -